Cargando…

Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?

Detalles Bibliográficos
Autor principal:	Schernthaner, Guntram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009615/ https://www.ncbi.nlm.nih.gov/pubmed/33798462 http://dx.doi.org/10.1016/S2213-8587(21)00059-0

Ejemplares similares

Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial
por: Schernthaner, G., et al.
Publicado: (2016)

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
por: Schernthaner, Guntram
Publicado: (2021)

The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
por: Czupryniak, Leszek, et al.
Publicado: (2021)

Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
por: Schernthaner, Guntram, et al.
Publicado: (2013)

COVID-19 antivirals must not affect HIV drug supply
por: Barber, Melissa, et al.
Publicado: (2022)

Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–1508
por: Home, Philip, et al.
Publicado: (2014)

Cure of Type 2 Diabetes by Metabolic Surgery? A Critical Analysis of the Evidence in 2010
por: Schernthaner, Guntram, et al.
Publicado: (2011)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
por: Schernthaner, Guntram, et al.
Publicado: (2018)

Targeting hyperinflammation in infection: can we harness the COVID-19 therapeutics momentum to end the dengue drugs drought?
por: McBride, Angela, et al.
Publicado: (2021)

Can the level of copper in the hippocampus witness type-II diabetes versus Alzheimer's disease?
por: Hureau, Christelle
Publicado: (2022)

Anticipating outcomes for patients with COVID-19 and identifying prognosis patterns
por: Darmon, Michael, et al.
Publicado: (2021)

COVID-19 and disparities affecting ethnic minorities
por: Morales, Daniel R, et al.
Publicado: (2021)

Can tocilizumab calm the cytokine storm of COVID-19?
por: Schulert, Grant S
Publicado: (2020)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

COVID-19, type 1 diabetes, and technology: why paediatric patients are leading the way
por: Danne, Thomas, et al.
Publicado: (2020)

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2017)

Insulin may increase disease severity and mortality of COVID-19 through Na(+)/H(+) exchanger in patients with type 1 and type 2 diabetes mellitus
por: Cure, E., et al.
Publicado: (2022)

Psychological interventions for people affected by the COVID-19 epidemic
por: Duan, Li, et al.
Publicado: (2020)

Offline: COVID-19—what we can expect to come
por: Horton, Richard
Publicado: (2020)

Can COVID-19 help accelerate and transform the diagnostics agenda?
por: Kleinert, Sabine, et al.
Publicado: (2021)

COVID-19 sequelae: can long-term effects be predicted?
por: Gavriilaki, Eleni, et al.
Publicado: (2022)

Fetuin-A Levels Are Increased in Patients With Type 2 Diabetes and Peripheral Arterial Disease
por: Lorant, David Peter, et al.
Publicado: (2011)

Renal Function but Not Asymmetric Dimethylarginine Is Independently Associated with Retinopathy in Type 2 Diabetes
por: Krzyzanowska, Katarzyna, et al.
Publicado: (2011)

Comment on Xiang et al. Association between the Triglyceride-Glucose Index and Vitamin D Status in Type 2 Diabetes Mellitus. Nutrients 2023, 15, 639
por: Mahat, Roshan Kumar, et al.
Publicado: (2023)

HIV, tuberculosis, and malaria: how can the impact of COVID-19 be minimised?
por: Sands, Peter
Publicado: (2020)

COVID-19 and psychiatry: can electronic medical records provide the answers?
por: Yolken, Robert
Publicado: (2021)

Azithromycin: can its benefit be ruled out in mild COVID-19?
por: Rodríguez-Molinero, Alejandro
Publicado: (2021)

Can COVID-19 changes reduce stigma in African HIV clinics?
por: Lofgren, Sarah M, et al.
Publicado: (2022)

Maternal mental health is being affected by poverty and COVID-19
por: Parra-Saavedra, Miguel, et al.
Publicado: (2021)

Integrative approaches required to support children affected by COVID-19
por: Goodman, Michael L, et al.
Publicado: (2022)

Catch me if you can: SARS-CoV-2 detection in brains of deceased patients with COVID-19
por: Frank, Stephan
Publicado: (2020)

Type 2 diabetes prevention goes digital
por: Samarasinghe, Suhaniya N.S., et al.
Publicado: (2022)

What can we expect from first-generation COVID-19 vaccines?
por: Peiris, Malik, et al.
Publicado: (2020)

BCG-induced trained immunity: can it offer protection against COVID-19?
por: O’Neill, Luke A. J., et al.
Publicado: (2020)

COVID-19 and other adult vaccines can drive global disease prevention
por: Agus, David B, et al.
Publicado: (2023)

How does diabetes mellitus impact on the prognosis of dental implants?
por: Baniulyte, Gabriele, et al.
Publicado: (2023)

Can ivermectin mass drug administrations to control scabies also reduce skin and soft tissue infections? Hospitalizations and primary care presentations lower after a large-scale trial in Fiji
por: Middleton, Jo
Publicado: (2022)

The effect of COVID-19 on routine diabetes care and mortality in people with diabetes
por: Hopkins, David, et al.
Publicado: (2022)

Antimicrobial use, drug-resistant infections and COVID-19
por: Rawson, Timothy M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_deuq77t70nrilonsarasbphanv